Trials / Recruiting
RecruitingNCT03925714
Impact of P53 and SIRT1 in Type 2 Diabetes
Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
Detailed description
Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | life style | life sryle control only |
| DRUG | Metformin | metformin twice daily |
| DRUG | Nigetella salivata | NS twice daily |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2019-04-24
- Last updated
- 2019-04-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03925714. Inclusion in this directory is not an endorsement.